Effects of Capsimax on Appetite, Energy Intake and Blood Pressure
Launched by LAVAL UNIVERSITY · Apr 30, 2021
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Premenopausal women
- • Between 18 and 50 years
- • Healthy
- • Non-smoker
- • BMI between 25 and 35 kg/m2
- • Weight stability
- Exclusion Criteria:
- • Pregnant or menopausal woman
- • History of losing and gaining weight (yo-yo)
- • Taking medication for diabetes, hypertension, depression, or hypothyroid
- • Taking a supplement for weight loss
- • Vegetarian, vegan, intolerant to gluten or pepper (investigational product), and severe allergy to peanuts or nuts
- • Suffers from Irritable Bowel Syndrome or gastro-oesophageal reflux
- • Suffers from stomach ulcers or inflammation
- • Other serious conditions such as cardiovascular, renal, liver, and lung diseases
- • History of drug abuse and current alcohol abuse
- • Use of any medication (including over-the-counter medications and herbal remedies) such as grapefruit juice, piperine, NSAIDs, etc.
About Laval University
Laval University is a prestigious research institution located in Quebec, Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. The university actively engages in clinical trials aimed at exploring new therapeutic interventions and improving patient outcomes. With a strong emphasis on ethical standards and rigorous scientific methodologies, Laval University collaborates with multidisciplinary teams of researchers, healthcare professionals, and industry partners to conduct high-quality clinical research. Its state-of-the-art facilities and dedication to fostering a culture of inquiry position Laval University as a leader in clinical research, contributing significantly to the understanding and treatment of diverse medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Québec, , Canada
Patients applied
Trial Officials
Angelo Tremblay
Principal Investigator
Laval University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials